Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 12Triple Negative Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Ovarian Neoplasms 5Fallopian Tube Neoplasms 4Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2Vaccinia 1Uterine Cervical Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Pathologic Complete Response 1Neuroendocrine Tumors 1Lymphoma, Non-Hodgkin 1Lymphoma 1HER2-negative Breast Cancer 1Gastric Adenocarcinoma 1Carcinoma, Small Cell 1Breast Diseases 1Brain Neoplasms 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Paclitaxel 15atezolizumab 11Gemcitabine 11Carboplatin 9pembrolizumab 8Docetaxel 8Irinotecan 7Bevacizumab 7Injections 6Cetuximab 6Sunitinib 5Leucovorin 5Fluorouracil 5Cyclophosphamide 5Capecitabine 5tocilizumab 4olaparib 4navitoclax 4liposomal doxorubicin 4Topotecan 4Oxaliplatin 4Nivolumab 4Erlotinib Hydrochloride 4temsirolimus 3spartalizumab 3pazopanib 3lenvatinib 3fludarabine 3cobimetinib 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Solid Tumors × taxane × Clear all
NCT07158918 2025-09-08

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

ABL Bio, Inc.

Phase 1/2 Recruiting
65 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡